Transdermal CBD Formulation for SYNGAP1 Seizure And Behavior Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a treatment of SYNGAP1 encephalopathy symptoms, including seizures and behavioral problems, that does not produce unwanted side effects such as somnolence, lethargy, withdrawal, or sedation, and exacerbate behavioral issues, as existing treatments like oral CBD have significant adverse events and psychoactive effects.
Innovation Solution
Transdermal administration of cannabidiol (CBD) in the range of 750 mg to 1000 mg daily, formulated as a gel, cream, salve, or lotion, to treat SYNGAP1 encephalopathy, targeting neuronal pathways and reducing adverse events associated with oral delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral CBD is administered to treat SYNGAP1 encephalopathy, then seizure reduction is achieved, but gastrointestinal adverse events and psychoactive effects occur
Solution Approach 1:
The patent uses transdermal delivery as an intermediary pathway to administer CBD, avoiding the gastrointestinal tract and liver first-pass metabolism. This mediator approach allows CBD to enter systemic circulation through the skin, achieving seizure reduction without gastrointestinal adverse events and minimizing psychoactive effects through controlled release.
Solution Approach 2:
The patent replaces the oral administration route (mechanical swallowing and gastrointestinal processing) with transdermal delivery (topical application and cutaneous absorption). This substitution eliminates the need for gastrointestinal processing and hepatic metabolism, thereby avoiding associated adverse events while maintaining therapeutic efficacy.
2Reliability
If high dose CBD is administered to treat SYNGAP1 encephalopathy, then behavioral problems are addressed, but somnolence and sedation worsen
Solution Approach 1:
The patent employs dynamic dosing through transdermal delivery, where the CBD release rate adjusts based on skin absorption characteristics and physiological conditions. This dynamic delivery system allows for sustained therapeutic levels for behavioral improvement while avoiding peak concentrations that cause excessive somnolence and sedation.
Solution Approach 2:
The patent changes the delivery parameter from oral to transdermal, fundamentally altering the pharmacokinetic profile of CBD. This parameter change results in slower, more sustained absorption that maintains effective levels for behavioral treatment while reducing the intensity of side effects like somnolence and sedation.
3Quantity of substance
If oral CBD is administered, then CBD reaches systemic circulation, but degradation in gastric acid occurs
Solution Approach 1:
The patent introduces transdermal absorption as an intermediary pathway that bypasses the gastrointestinal environment. CBD is delivered through the skin directly to systemic circulation, avoiding exposure to gastric acid and the associated degradation that occurs with oral administration.
Solution Approach 2:
The patent extracts CBD from the oral administration pathway and delivers it through an alternative route. By removing CBD from the gastrointestinal environment entirely and delivering it transdermally, the patent prevents gastric acid degradation while ensuring systemic circulation delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Transdermal CBD effectively reduces SYNGAP1 seizures by up to 73% and improves behavioral problems, enhancing daily satisfaction, cognition, and well-being, while minimizing adverse events like somnolence and gastrointestinal issues.
Implementation Method 1
transdermal administration of cannabidiol (CBD) in the range of 750 mg to 1000 mg daily, formulated as a gel, cream, salve, or lotion
Data Source
Figure 1
AI summary
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.